You are here

First Emergency Hypoglycemia Treatment, No Injection Needed

Approved for Patients Ages 4 and Up

The FDA has approved glucagon nasal powder 3 mg (Baqsimi, Eli Lilly and Company), the first glucagon therapy for the emergency treatment of severe hypoglycemia that can be administered without an injection. The agent is approved to treat severe hypoglycemia in patients with diabetes from the age of 4 years.

Until now, anyone suffering from a severe hypoglycemic episode had to be treated with a glucagon injection, which requires being mixed in a several-step process beforehand. The new method of administering glucagon could simplify the process, which can be critical during an episode, especially as the patient may have lost consciousness or may be having a seizure.

Glucagon nasal powder will be available in a single-use dispenser that can be given to someone who is having a severe hypoglycemic episode. The drug increases blood sugar levels in the body by stimulating the liver to release stored glucose into the bloodstream.

Injectable glucagon has been used in the United States for several decades. The approval of glucagon nasal powder was based on data from three studies of people with type-1 diabetes: one involved 70 adults, one involved 83 adults, and the third involved 48 children aged 4 years or older.

Glucagon nasal powder is not recommended for patients with pheochromocytoma or those with insulinoma.

The most common adverse reactions associated with glucagon nasal powder are nausea, vomiting, headache, upper respiratory tract irritation, watery eyes, redness of eyes, and itchiness.

Source: FDA, July 25, 2019

Recent Headlines

More research is needed to confirm the finding
Study shows "complex genetic risk architecture"
Study says yes, interventions cuts need for meds
Review of 18 studies finds that medium doses have the strongest effects
Research suggests that stress mitigation could be an effective intervention strategy
Children, parents with ADHD benefit from parenting intervention
Your heart will thank you
Seems like the 2013 Guidelines are having an impact
Biomarker blood tests pick up subtle clues